Immunome Inc Asset Resilience Ratio
Immunome Inc asset resilience ratio. Immunome Inc (IMNM) has an Asset Resilience Ratio of 53.47% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Immunome Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Immunome Inc (2022–2025)
Asset resilience ratio of Immunome Inc from 2022 to 2025. This chart shows how Immunome Inc's Asset Resilience Ratio has changed over time. Read Immunome Inc (IMNM) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Immunome Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Immunome Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $302.29 Million | 53.47% |
| Total Liquid Assets | $302.29 Million | 53.47% |
Asset Resilience Insights
- Very High Liquidity: Immunome Inc maintains exceptional liquid asset reserves at 53.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immunome Inc Industry Peers by Asset Resilience Ratio
Compare Immunome Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Immunome Inc Asset Resilience Ratio by Year (2022–2025)
Immunome Inc asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Immunome Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $683.19 Million | -- |
| 2024-12-31 | 30.78% | $73.95 Million | $240.24 Million | +4.22pp |
| 2023-12-31 | 26.57% | $39.46 Million | $148.54 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $24.05 Million | -- |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more